Table 1.
Clinical data of 238 nasopharyngeal carcinoma patients
| Pre-treatment BMI, kg/m2 | ||||
|---|---|---|---|---|
| Variable | All | <23 (N = 81) | ≥23 (N = 157) | p |
| Age, y | 50.26 ± 11.82 | 49.02 ± 12.84 | 50.09 ± 11.24 | 0.246 |
| Sex (%) | <0.001 | |||
| male | 169(71.0) | 45(55.6) | 124(79.0) | |
| female | 69(29.0) | 36(44.4) | 33(21.0) | |
| Smoke (%) | 0.106 | |||
| No | 160(67.2) | 60(74.1) | 100(63.7) | |
| Yes | 78(32.8) | 21(25.9) | 57(36.3) | |
| CCIS (%) | 0.742 | |||
| 0 | 184(77.3) | 64(79.0) | 120(76.4) | |
| 1 | 32(13.4) | 9(11.1) | 23(14.6) | |
| ≥2 | 22(9.2) | 8(9.9) | 14(8.9) | |
| Histology type | 0.082 | |||
| NUC | 214(89.9) | 69(85.2) | 145(92.4) | |
| NDC | 24(10.1) | 12(14.8) | 12(7.6) | |
| T classification (%) | 0.253 | |||
| T1/T2 | 121(50.8) | 37(45.7) | 84(53.5) | |
| T3/T4 | 117(49.2) | 44(54.3) | 73(46.5) | |
| N classification (%) | 0.779 | |||
| N0/N1 | 62(26.1) | 22(27.2) | 40(25.5) | |
| N2/N3 | 176(73.9) | 59(72.8) | 117(74.5) | |
| AJCC Stage (%) | 0.775 | |||
| Stage 1/2 | 36(15.1) | 13(16.0) | 23(14.6) | |
| Stage 3/4 | 202(84.9) | 68(84.0) | 134(85.4) | |
| Treatment arm (%) | 0.592 | |||
| RT alone | 41(17.2) | 15(18.5) | 26(16.6) | |
| CCRT alone | 93(39.1) | 28(34.6) | 65(41.4) | |
| RT/CCRT + CT | 104(43.7) | 38(46.9) | 66(42.0) | |
| BWL (%) | 0.003 | |||
| <5 % | 88(37.0) | 41(50.6) | 47(29.9) | |
| ≥5 % | 150(63.0) | 40(49.4) | 110(70.1) | |
| Education level (%) | 0.97 | |||
| Low | 113(47.5) | 39(48.1) | 74(47.1) | |
| Medium | 70(29.4) | 23(28.4) | 47(29.9) | |
| High | 55(23.1) | 19(23.5) | 36(22.9) | |
| RT duration | 7.46 ± 0.77 | 7.58 ± 0.80 | 7.40 ± 0.75 | 0.091 |
| Hemoglobin | 13.85 ± 1.77 | 13.28 ± 1.66 | 14.15 ± 1.75 | 0.001 |
CCIS Charlson Comorbidity Index Score; NUC nonkeratinizing undifferentiated carcinoma; NDC nonkeratinizing differentiated carcinoma; BMI body mass index; BWL body weight loss; RT radiotherapy; CT chemotherapy; CCRT concurrent chemoradiotherapy
Values are numbers (percentage)